Ruxolitinib: all 324 studies that test it
Page 3 of 4. Open to participants first (83), then studies with results posted, then the rest; newest registration first within each.
- A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple MyelomaCompletedNCT00639002Phase 2Results posted
- Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate CancerTerminatedNCT00638378Phase 2Results posted
- Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With PsoriasisCompletedNCT00617994Phase 2Results posted
- A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid ArthritisCompletedNCT00550043Phase 2Results posted
- Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia MyelofibrosisCompletedNCT00509899Phase 1/2Results posted
- A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult ParticipantsCompletedNCT07588139Phase 1
- Comparative Effectiveness of Ruxolitinib Monotherapy Versus Its Combination With Tacrolimus and Corticosteroids in the Management of Vitiligo: A Randomized Controlled TrialCompletedNCT07368673Phase 4
- Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With MyelofibrosisActive, not recruitingNCT07340138Phase 1
- Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)Active, not recruitingNCT06959225Phase 3
- Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)Active, not recruitingNCT06958211Phase 3
- A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic DermatitisActive, not recruitingNCT06832618Phase 3
- CART123 + Ruxolitinib in Relapsed/Refractory AMLActive, not recruitingNCT06768476Phase 1
- Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic AnemiaActive, not recruitingNCT06752694Phase 2
- Upfront Ruxolitinib for Chronic Graft-vs-host DiseaseTerminatedNCT06695507Phase 1
- A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With MyelofibrosisWithdrawnNCT06619522Phase 2
- A Study to Evaluate the Bioequivalence of Ruxolitinib Extended Release (XR) Tablets With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy ParticipantsCompletedNCT06555081Phase 1
- Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host DiseaseActive, not recruitingNCT06462469Phase 4
- RVU120 in Patients With Intermediate or High-risk, Primary or Secondary MyelofibrosisTerminatedNCT06397313Phase 2
- A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host DiseaseActive, not recruitingNCT06388564Phase 2
- A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants.CompletedNCT06310304Phase 1
- A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib CreamCompletedNCT06213831Phase 1
- A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmsActive, not recruitingNCT05936359Phase 1
- Efficacy and Safety of Ruxolitinib in Neuromyelitis Optica Spectrum DisordersWithdrawnNCT05909943Phase 1/2
- The Efficacy and Safety of Corticosteroids in Combination With Ruxolitinib in the Management of Checkpoint Inhibitor PneumoniaCompletedNCT05899725Not applicable
- Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host DiseaseCompletedNCT05663827Phase 3
- De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) ProphylaxisActive, not recruitingNCT05622318Phase 2
- Prevention of Severe Acute Graft-versus-host Disease in Adult Patients Using a daGOAT ModelCompletedNCT05600855Phase 2
- A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in MyelofibrosisStatus unknownNCT05447260Phase 4
- Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal AdenocarcinomaCompletedNCT05440942Phase 1
- Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans SyndromeStatus unknownNCT05413356Phase 2
- A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With MyelofibrosisActive, not recruitingNCT05371964Phase 1
- Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2WithdrawnNCT05233410Phase 3
- Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1WithdrawnNCT05219864Phase 3
- Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation SyndromeStatus unknownNCT05137496Phase 3
- Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated CorticosteroidsTerminatedNCT05123040Phase 1/2
- Study of Ruxolitinib for Acute and Chronic Graft Versus Host DiseaseCompletedNCT05121142Phase 1
- Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted GraftActive, not recruitingNCT05088356Phase 1
- Study of Ruxolitinib Cream in Children With Atopic DermatitisCompletedNCT05034822Phase 1
- Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHDStatus unknownNCT05021276Phase 4
- A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome.Status unknownNCT04999878Phase 4
- Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell TransplantTerminatedNCT04908735Phase 2
- Ruxolitinib With Calcineurin Inhibitor and Methotrexate vs. Calcineurin Inhibitor Plus Methotrexate and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis for HLA-haploidentical Hematopoietic Stem Cell TransplantationCompletedNCT04838704Not applicable
- A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)Active, not recruitingNCT04817007Phase 1/2
- PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCTCompletedNCT04669210Phase 2
- Inflammatory Signal Inhibitors for COVID-19 (MATIS)CompletedNCT04581954Phase 1/2
- Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic LymphohistiocytosisActive, not recruitingNCT04551131Phase 1/2
- Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)Active, not recruitingNCT04509700Phase 2
- An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to RuxolitinibStatus unknownNCT04485260Phase 1/2
- Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With MyelofibrosisTerminatedNCT04480086Phase 1
- Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19TerminatedNCT04477993Phase 2/3
- Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory MyelofibrosisActive, not recruitingNCT04468984Phase 3
- Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With MyelofibrosisActive, not recruitingNCT04454658Phase 1
- Prevention and Treatment of Differentiation Syndrome in Patients With Acute Promyelocytic LeukemiaStatus unknownNCT04446806Phase 4
- A Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated DiseaseStatus unknownNCT04424056Phase 3
- Ruxolitinib in the Treatment of Covid-19Status unknownNCT04414098Phase 2
- COLchicine Versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients With COVID-19CompletedNCT04403243Phase 2
- Low Dose Ruxolitinib in Combination With MethylprednisoloneCompletedNCT04397367Phase 1/2
- Peritransplant Ruxolitinib for Patients With Primary and Secondary MyelofibrosisActive, not recruitingNCT04384692Phase 2
- Ruxolitinib to Combat COVID-19WithdrawnNCT04354714Phase 2
- Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.CompletedNCT04348695Phase 2
- Safety and Efficacy of Ruxolitinib for COVID-19WithdrawnNCT04348071Phase 2/3
- Ruxolitinib in Covid-19 Patients With Defined HyperinflammationCompletedNCT04338958Phase 2
- Treatment of SARS Caused by COVID-19 With RuxolitinibCompletedNCT04334044Phase 1/2
- Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 PneumoniaTerminatedNCT04331665Not applicable
- Fecal Microbiota Transplantation With Ruxolitinib and Steroids as an Upfront Treatment of Severe Acute Intestinal GVHDTerminatedNCT04269850Phase 1/2
- Actuate 1901: 9-ING-41 in MyelofibrosisCompletedNCT04218071Phase 2
- Ruxolitinib as a Salvage Therapy for Hemophagocytic LymphohistiocytosisStatus unknownNCT04120090Phase 3
- First Line Therapy for High Risk Acute GVHDCompletedNCT04061876Phase 2
- A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmActive, not recruitingNCT04041050Phase 1
- Dual PD-1 and JAK2 Inhibition in Hematological MalignanciesWithdrawnNCT04016116Phase 2
- A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic DermatitisCompletedNCT03920852Phase 1
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic DisordersActive, not recruitingNCT03801434Phase 2
- Ruxolitinib Combined With Dexamethasone for HLHStatus unknownNCT03795909Phase 1/2
- Ruxolitinib and Steroid As First Line Therapy for Acute GVHDTerminatedNCT03701698Phase 2
- Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)Active, not recruitingNCT03674047Phase 2
- Ruxolitinib Plus LVP in Patients With R/R ETP-ALLStatus unknownNCT03613428Phase 1/2
- Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase InhibitorsActive, not recruitingNCT03610971Phase 2
- The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative NeoplasmStatus unknownNCT03558607Phase 1/2
- Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With MyelofibrosisTerminatedNCT03386214Phase 1
- Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of MyelofibrosisTerminatedNCT03373877Phase 1
- Ruxolitinib + Allogeneic Stem Cell Transplantation in AMLActive, not recruitingNCT03286530Phase 2
- Effect of Ruxolitinib on Tumor Infiltrating Myeloid CellsWithdrawnNCT03274778Not applicable
- A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic DermatitisCompletedNCT03257644Phase 1
- Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and LymphomaActive, not recruitingNCT03117751Phase 2/3
- A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With MyelofibrosisActive, not recruitingNCT03069326Phase 2
- Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast CancerCompletedNCT03012230Phase 1
- Ruxolitinib for Steroid-refractory GVHDCompletedNCT02997280Phase 2
- A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CMLWithdrawnNCT02973711Phase 1/2
- The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second LineTerminatedNCT02962388Phase 2/3
- An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of RuxolitinibActive, not recruitingNCT02955940Phase 2
- Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With MyelofibrosisCompletedNCT02917096Phase 1
- Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia PatientsStatus unknownNCT02912754Phase 1/2
- PTCy and Ruxolitinib GVHD Prophylaxis in MyelofibrosisCompletedNCT02806375Phase 1/2
- Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPegCompletedNCT02742324Phase 1/2
- A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic LeukemiaCompletedNCT02723994Phase 2
- Genomics-Based Target Therapy for Children With Relapsed or Refractory MalignancyStatus unknownNCT02638428Phase 2
- Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory LymphomaCompletedNCT02613598Phase 1
- Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck CancerWithdrawnNCT02593929Early Phase 1
- The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential ThrombocythemiaActive, not recruitingNCT02577926Phase 2